8-K: Cidara Therapeutics Suspends At-The-Market Stock Offering Prospectus

Cidara Therapeutics, Inc. announced the suspension and termination of its at-the-market (ATM) common stock offering prospectus with Jefferies LLC, effective June 24, 2025.

Summary

• Cidara Therapeutics, Inc. delivered written notice to Jefferies LLC on June 24, 2025, to suspend and terminate the prospectus related to its common stock.
• The prospectus, dated May 15, 2025, was for sales of common stock pursuant to an Open Market Sale AgreementSM dated May 8, 2025, between Cidara and Jefferies.
• The Company will not make any sales of its common stock under the Sales Agreement unless and until a new prospectus or prospectus supplement is filed with the SEC.
• Other than the termination of the ATM Prospectus, the underlying Sales Agreement remains in full force and effect.
• The Sales Agreement was previously filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q on May 8, 2025.

Sentiment

Score: 5

Explanation: The document is a factual report of a procedural change regarding a capital raising mechanism. It does not provide context or reasons for the suspension, thus maintaining a neutral sentiment.

Future Outlook

The Company will not make any sales of its common stock pursuant to the Sales Agreement, unless and until a new prospectus or prospectus supplement is filed with the Securities and Exchange Commission.

Industry Context

This announcement reflects a procedural change in Cidara Therapeutics' capital raising strategy, specifically regarding its at-the-market equity program. Such adjustments are common in the biotechnology sector, where companies frequently manage their capital structure based on funding needs, market conditions, and strategic priorities.

Stakeholder Impact

• Shareholders: The suspension of the ATM prospectus means the company will not be diluting existing shares through this specific mechanism for the time being, unless a new prospectus is filed. This could be viewed positively by some investors concerned about dilution, or negatively by those who anticipated capital infusion.

Next Steps

• If the Company wishes to resume sales of common stock under the Sales Agreement, it will need to file a new prospectus or prospectus supplement with the SEC.

Key Dates

Keywords

Cidara Therapeutics, CDTX, ATM offering, At-The-Market, common stock, prospectus suspension, Jefferies LLC, SEC filing, 8-K, capital markets